How can we improve the translational landscape for a faster cure of type 1 diabetes?
Translation of novel therapies for type 1 diabetes and other autoimmune diseases to the clinic has been slow despite significant new initiatives from funding agencies. One reason for this is that different incentives drive industry, academia, and funding bodies. These communities therefore lack common goals and often communicate poorly, resulting in unintended obstacles that hamper progress in efficiently translating basic scientific discoveries into medical practice. Here, based on our own personal experiences, we discuss some of the drivers within each community that cause these problems, existing mechanisms to facilitate the translation of science into medical practice, and remaining issues that need to be solved.
La Jolla Institute for Allergy and Immunology, California 92037, USA. matthias@liai.org
Matthias
M
von Herrath
Andrew
A
Chan
D000047:Academies and Institutes / Q000191:economics; D003142:Communication; D003299:Cooperative Behavior; D003922:Diabetes Mellitus, Type 1 / Q000628:therapy*; D055808:Drug Discovery / Q000191:economics; D004345:Drug Industry / Q000191:economics; D004359:Drug Therapy, Combination; D006801:Humans; D018973:Intellectual Property; D055818:Public-Private Sector Partnerships; D013997:Time Factors